Evidence map›Paper›PMID 34823578›Full record

ArticleBMC research notes2021

Development and validation of an equation to predict the incidence of coronary heart disease in patients with type 2 diabetes in Japan.

Yasunari Yamashita, Gaku Inoue, Yoichi Nozaki, Rina Kitajima, Kiyoshi Matsubara, Takeshi Horii, Junichi Mohri, Koichiro Atsuda, Hajime Matsubara

Abstract read
In one paragraph

Article in BMC research notes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yasunari YamashitaDivision of Clinical Pharmacy (Laboratory of Pharmacy Practice and Science III), and Research and Education Center for Clinical Pharmacy, School of Pharmacy, Kitasato University, 9-1, Shirokane 5-Chome, Minato-ku, Tokyo, 108-8641, Japan. dp18205@st.kitasato-u.ac.jp.ORCID http://orcid.org/0000-0002-4006-2770
Gaku InoueDivision of Clinical Pharmacy (Laboratory of Pharmacy Practice and Science III), and Research and Education Center for Clinical Pharmacy, School of Pharmacy, Kitasato University, 9-1, Shirokane 5-Chome, Minato-ku, Tokyo, 108-8641, Japan.
Yoichi NozakiDivision of Clinical Pharmacy (Laboratory of Pharmacy Practice and Science III), and Research and Education Center for Clinical Pharmacy, School of Pharmacy, Kitasato University, 9-1, Shirokane 5-Chome, Minato-ku, Tokyo, 108-8641, Japan.
Rina KitajimaDivision of Clinical Pharmacy (Laboratory of Pharmacy Practice and Science III), and Research and Education Center for Clinical Pharmacy, School of Pharmacy, Kitasato University, 9-1, Shirokane 5-Chome, Minato-ku, Tokyo, 108-8641, Japan.
Kiyoshi MatsubaraDivision of Clinical Pharmacy (Laboratory of Pharmacy Practice and Science III), and Research and Education Center for Clinical Pharmacy, School of Pharmacy, Kitasato University, 9-1, Shirokane 5-Chome, Minato-ku, Tokyo, 108-8641, Japan.
Takeshi HoriiDivision of Clinical Pharmacy (Laboratory of Pharmacy Practice and Science I), and Research and Education Center for Clinical Pharmacy, School of Pharmacy, Kitasato University, 1-15-1 Kitasato, Minami Ward, Sagamihara, Kanagawa, 252-0375, Japan.
Junichi MohriDivision of Clinical Pharmacy (Laboratory of Pharmacy Practice and Science I), and Research and Education Center for Clinical Pharmacy, School of Pharmacy, Kitasato University, 1-15-1 Kitasato, Minami Ward, Sagamihara, Kanagawa, 252-0375, Japan.
Koichiro AtsudaDivision of Clinical Pharmacy (Laboratory of Pharmacy Practice and Science I), and Research and Education Center for Clinical Pharmacy, School of Pharmacy, Kitasato University, 1-15-1 Kitasato, Minami Ward, Sagamihara, Kanagawa, 252-0375, Japan.
Hajime MatsubaraDivision of Clinical Pharmacy (Laboratory of Pharmacy Practice and Science III), and Research and Education Center for Clinical Pharmacy, School of Pharmacy, Kitasato University, 9-1, Shirokane 5-Chome, Minato-ku, Tokyo, 108-8641, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveIn the diabetes treatment policy after the Kumamoto Declaration 2013, it is difficult to accurately predict the incidence of complications in patients using the JJ risk engine. This study was conducted to develop a prediction equation suitable for the current diabetes treatment policy using patient data from Kitasato University Kitasato Institute Hospital (Hospital A) and to externally validate the developed equation using patient data from Kitasato University Hospital (Hospital B). Outlier tests were performed on the patient data from Hospital A to exclude the outliers. Prediction equation was developed using the patient data excluding the outliers and was subjected to external validation.

resultsBy excluding outlier data, we could develop a new prediction equation for the incidence of coronary heart disease (CHD) as a complication of type 2 diabetes, incorporating the use of antidiabetic drugs with a high risk of hypoglycemia. This is the first prediction equation in Japan that incorporates the use of antidiabetic drugs. We believe that it will be useful in preventive medicine for treatment for people at high risk of CHD as a complication of diabetes or other diseases. In the future, we would like to confirm the accuracy of this equation at other facilities.

Indexed as

Coronary DiseaseDiabetes Mellitus, Type 2HumansIncidenceJapanRisk AssessmentRisk FactorsBox plotCalibrationCoronary heart diseaseC-statisticDiscriminationHypoglycemiaJJ risk engineOutlierType 2 diabetes

Identifiers

PMID34823578
PMCPMC8613942

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.